Revive Therapeutics Applies For Orphan Drug Designation For Psilocybin
Revive Therapeutics (CSE: RVV) has filed for orphan drug designation with the US Food and Drug Administration. The filing relates
Read more
Revive Therapeutics
Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin
Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an oral thin film delivery system
Read more
Revive Therapeutics Reports Successful Results Using Psilocybin To Treat Traumatic Brain Injury
Revive Therapeutics (CSE: RVV) this morning revealed that it has received positive results for a pre-clinical study that evaluated the
Read more
Revive Therapeutics To Expand Clinical Sites For Covid-19 Related Phase 3 Study
Revive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase 3 clinical trial for the
Read more
PharmaTher, Revive, Complete Psilocybin Intellectual Property Transaction
PharmaTher (CSE: PHRM) has seen the completion of the sale of its psilocybin program to that of Revive Therapeutics (CSE:
Read more
Revive Therapeutics Closes $23.0 Million Bought Deal Financing
Revive Therapeutics (CSE: RVV) this morning announced the closing of its bought deal financing. Originally announced at a figure of
Read more
Revive Therapeutics Provides Market Update On Cannabinoid Related Research
Revive Therapeutics (CSE: RVV) this morning provided an update in connection with its ongoing cannabinoid pharmaceuticals program. More specifically, the
Read more
Revive Therapeutics Doubles Bought Deal Financing To $20.0 Million
Revive Therapeutics (CSE: RVV) has upsized the bought deal financing announced last night. Originally pegged at $10.0 million in gross
Read more
Revive Therapeutics Conducts $10.0 Million Bought Deal Financing
Revive Therapeutics (CSE: RVV) this evening announced that it will be conducting a bought deal financing, lead by Leede Jones
Read more
Revive Therapeutics Announces Research Collaboration For Natural Psilocybin Biosynthesis
Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a sponsored research collaboration agreement, as well as
Read more